NCT03671785 is a Phase 1 clinical trial of PRIM-DJ2727 in Parkinson Disease, sponsored by The University of Texas Health Science Center, Houston.

Who is sponsoring NCT03671785?

NCT03671785 is sponsored by The University of Texas Health Science Center, Houston.

What drugs are being tested in NCT03671785?

Interventions in NCT03671785: PRIM-DJ2727, Placebo oral capsule.

What condition does NCT03671785 study?

NCT03671785 studies Parkinson Disease.

Is NCT03671785 still recruiting?

NCT03671785 is currently completed. Last updated 24 May 2023.

Last reviewed 2023-05-24 · How we verify

NCT03671785

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Fecal Microbiome in Patients With Parkinson's Disease

Completed Phase 1 Last updated 24 May 2023

What this trial tests

Phase 1 trial testing PRIM-DJ2727 in Parkinson Disease in 15 participants. Completed in 12 October 2022.

Timeline

15 May 2019

Primary endpoint
9 October 2022

12 October 2022

Quick facts

Lead sponsor	The University of Texas Health Science Center, Houston
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	15
Start date	15 May 2019
Primary completion	9 October 2022
Estimated completion	12 October 2022
Sites	1 location across United States

Drugs / interventions tested

PRIM-DJ2727 — full drug profile →
Placebo oral capsule

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

The University of Texas Health Science Center, Houston

Who can join

Adults 55 to 75, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the intestinal microbiome in subjects with Parkinson's disease and to determine safety and trends in improvements in diversity of colonic microbiome following administration of lyophilized PRIM-DJ2727

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases.
Loh JS, Mak WQ, Tan LKS, Ng CX, et al · · 2024 · cited 631× · PMID 38360862 · DOI 10.1038/s41392-024-01743-1
Fecal microbiota transplantation beyond Clostridioides difficile infections.
Wortelboer K, Nieuwdorp M, Herrema H. · · 2019 · cited 111× · PMID 31201141 · DOI 10.1016/j.ebiom.2019.05.066
Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study.
DuPont HL, Suescun J, Jiang ZD, Brown EL, et al · · 2023 · cited 98× · PMID 36937520 · DOI 10.3389/fneur.2023.1104759
Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain.
Xu HM, Huang HL, Zhou YL, Zhao HL, et al · · 2021 · cited 59× · PMID 33510784 · DOI 10.1155/2021/6699268
The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
Menozzi E, Schapira AHV. · · 2024 · cited 22× · PMID 38570412 · DOI 10.1007/s40263-024-01073-4
Therapies for Parkinson's disease and the gut microbiome: evidence for bidirectional connection.
Hey G, Nair N, Klann E, Gurrala A, et al · · 2023 · cited 17× · PMID 37323145 · DOI 10.3389/fnagi.2023.1151850
The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications.
Menozzi E, Schapira AHV, Borghammer P. · · 2025 · cited 11× · PMID 40079755 · DOI 10.1002/mdc3.70029
Recent advances in understanding and treatment of Parkinson's disease.
Tarakad A, Jankovic J. · · 2020 · cited 10× · PMID 33659938 · DOI 10.12703/b/9-6

Verify or expand the search:

Other trials of PRIM-DJ2727

Trials testing the same drug.

NCT06827977 — A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Sys · Phase 2 · recruiting
NCT04371653 — A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the · Phase 2 · withdrawn
NCT04373473 — Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of · Phase 2 · recruiting
NCT04729790 — Randomized Clinical Trial of Standard FMT Treatments · Phase 2 · withdrawn
NCT03026231 — Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients · Phase 1, PHASE2 · withdrawn

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other The University of Texas Health Science Center, Houston trials

Trials by the same sponsor.

NCT04200729 — Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-cente · Phase 4 · not yet recruiting
NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
NCT07396974 — Increasing Treatment Access in Trauma Exposed Children: Developing an Adapted Step One Intervention (RCT) · NA · not yet recruiting
NCT07170163 — Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families · NA · not yet recruiting
NCT06915441 — Lipid Infusions to Optimize Nutrition Trial · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03671785 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center, Houston
Last refreshed: 24 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03671785.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing